By binding to TIM-3 on DCs, LGALS9 disrupts antigen recognition, processing, and presentation, thereby impairing downstream cytotoxic T cell activation, a process that mirrors findings from functional experiments demonstrating TIM-3-dependent DC paralysis in glioma [24,25]. Here, LGALS9 is linked to central nervous system cancer.